Inventiva Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Inventiva (EPA:IVA) Full Year 2023 Results

Key Financial Results

• Revenue: €23.2m (up 23% from FY 2022).
• Net loss: €110.4m (loss widened by 103% from FY 2022).
• €2.44 loss per share (further deteriorated from €1.31 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Inventiva Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 85%. Earnings per share (EPS) missed analyst estimates by 13%.

Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 36% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's shares are down 5.1% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 5 warning signs for Inventiva you should be aware of, and 2 of them make us uncomfortable.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.